Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 301–400 of 1,005
Tantry, U. S., Bliden, K. P., Wei, C., Storey, R. F., Armstrong, M., Butler, K., & Gurbel, P. A. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.958561 · Cited by 182
Self-citationNikolaou, N. I., Arntz, H.-R., Bellou, A., Beygui, F., Bossaert, L. L., Cariou, A., & Danchin, N. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.07.030 · Cited by 182
Hagström, E., James, S. K., Bertilsson, M., Becker, R. C., Himmelmann, A., Husted, S., Katus, H. A., Steg, P. G., Storey, R. F., Siegbahn, A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv491 · Cited by 181
Self-citationCapodanno, D., Mehran, R., Krucoff, M. W., Baber, U., Bhatt, D. L., Capranzano, P., Collet, J.-P., Cuisset, T., De Luca, G., De Luca, L., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064473 · Cited by 179
Self-citationAbraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.445 · Cited by 179
Self-citationSwitching P2Y12-receptor inhibitors in patients with coronary artery disease
Rollini, F., Franchi, F., & Angiolillo, D. J. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.113 · Cited by 177
Mortality Rate in Type 2 Myocardial Infarction: Observations from an Unselected Hospital Cohort
Saaby, L., Poulsen, T. S., Diederichsen, A. C. P., Hosbond, S., Larsen, T. B., Schmidt, H., Gerke, O., Hallas, J., Thygesen, K., & Mickley, H. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.12.020 · Cited by 176
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Inker, L. A., Collier, W., Greene, T., Miao, S., Chaudhari, J., Appel, G. B., Badve, S. V., Caravaca-Fontán, F., Del Vecchio, L., Floege, J., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02418-0 · Cited by 171
Self-citationVrijens, B., & Heidbuchel, H. (2015) · Europace · doi:10.1093/europace/euu311 · Cited by 172
Johnston, N., Bodegard, J., Jerström, S., Åkesson, J., Brorsson, H., Alfredsson, J., Albertsson, P. A., Karlsson, J.-E., & Varenhorst, C. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.05.005 · Cited by 172
Chew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. (2016) · Medical Journal of Australia · doi:10.5694/mja16.00368 · Cited by 173
Diagnosis and Management of Acute Coronary Syndrome: An Evidence-Based Update
Smith, J. N., Negrelli, J. M., Manek, M. B., Hawes, E. M., & Viera, A. J. (2015) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2015.02.140189 · Cited by 170
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
Pereira, N. L., Rihal, C., Lennon, R., Marcus, G., Shrivastava, S., Bell, M. R., So, D., Geller, N., Goodman, S. G., Hasan, A., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.01.024 · Cited by 166
Hong, S.-J., Lee, S.-J., Suh, Y., Yun, K. H., Kang, T. S., Shin, S., Kwon, S. W., Lee, J.-W., Cho, D.-K., Park, J.-K., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066943 · Cited by 167
Population Trends in Percutaneous Coronary Intervention
Fokkema, M. L., James, S. K., Albertsson, P., Akerblom, A., Calais, F., Eriksson, P., Jensen, J., Nilsson, T., de Smet, B. J., Sjögren, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.007 · Cited by 170
Self-citationImportance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s61438 · Cited by 168
The Differential Diagnosis of Dyspnea
Berliner, D., Schneider, N., Welte, T., & Bauersachs, J. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0834 · Cited by 163
Jneid, H., Addison, D., Bhatt, D. L., Fonarow, G. C., Gokak, S., Grady, K. L., Green, L. A., Heidenreich, P. A., Ho, P. M., Jurgens, C. Y., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000032 · Cited by 168
“9% rate of recurrent MI at 12 months.(7) In 2010 alone, about 595 000 inpatient hospital discharges were attributed to AMI.”
BackgroundInfluentialYou, S. C., Rho, Y., Bikdeli, B., Kim, J., Siapos, A., Weaver, J., Londhe, A., Cho, J., Park, J., Schuemie, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.16167 · Cited by 171
Cerrato, E., Giacobbe, F., Quadri, G., Macaya, F., Bianco, M., Mori, R., Biolè, C. A., Boi, A., Bettari, L., Rolfo, C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab372 · Cited by 167
Antithrombotic Therapy in Patients With Chronic Kidney Disease
Capodanno, D., & Angiolillo, D. J. (2012) · Circulation · doi:10.1161/circulationaha.111.084996 · Cited by 165
Motovska, Z., Hlinomaz, O., Kala, P., Hromadka, M., Knot, J., Varvarovsky, I., Dusek, J., Jarkovsky, J., Miklik, R., Rokyta, R., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.008 · Cited by 165
“Prasugrel and ticagrelor, compared with clopidogrel, have shown higher efficacy in terms of reducing major cardiovascular events, relative to the increased risk of major bleeding (7,8).”
BackgroundResultLevine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2012) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23438 · Cited by 166
Hess, C. N., Norgren, L., Ansel, G. M., Capell, W. H., Fletcher, J. P., Fowkes, F. G. R., Gottsäter, A., Hitos, K., Jaff, M. R., Nordanstig, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.024469 · Cited by 165
Radico, F., Zimarino, M., Fulgenzi, F., Ricci, F., Di Nicola, M., Jespersen, L., Chang, S. M., Humphries, K. H., Marzilli, M., & De Caterina, R. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy185 · Cited by 165
(2011) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2011.03.008 · Cited by 163
F. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
“Following an episode of ACS, dual antiplatelet therapy given for a period of 12 months is a standard treatment based on results from the CURE [455], TRITON [456] and PLATO [457] studies, whereas no clinical studies support the use of prasugrel and ticagrelor in patients with stable CAD.”
Storey, R. F., James, S. K., Siegbahn, A., Varenhorst, C., Held, C., Ycas, J., Husted, S. E., Cannon, C. P., Becker, R. C., Steg, P. G., et al. (2014) · Platelets · doi:10.3109/09537104.2013.842965 · Cited by 162
Self-citationBleeding avoidance strategies in percutaneous coronary intervention
Capodanno, D., Bhatt, D. L., Gibson, C. M., James, S., Kimura, T., Mehran, R., Rao, S. V., Steg, P. G., Urban, P., Valgimigli, M., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00598-1 · Cited by 162
Self-citationRao, S. V., Kirsch, B., Bhatt, D. L., Budaj, A., Coppolecchia, R., Eikelboom, J., James, S. K., Jones, W. S., Merkely, B., Keller, L., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061612 · Cited by 158
Self-citationSahlén, A., Varenhorst, C., Lagerqvist, B., Renlund, H., Omerovic, E., Erlinge, D., Wallentin, L., James, S. K., & Jernberg, T. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw284 · Cited by 161
Self-citationSumaya, W., Wallentin, L., James, S. K., Siegbahn, A., Gabrysch, K., Bertilsson, M., Himmelmann, A., Ajjan, R. A., & Storey, R. F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy013 · Cited by 160
“The study design and results have previously been published.(1,20) Baseline patient characteristics, including medical and medication history, were recorded at baseline.”
ResultSelf-citationSex differences in mechanisms, presentation and management of ischaemic heart disease
Crea, F., Battipaglia, I., & Andreotti, F. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.802 · Cited by 159
Angiolillo, D. J., Schneider, D. J., Bhatt, D. L., French, W. J., Price, M. J., Saucedo, J. F., Shaburishvili, T., Huber, K., Prats, J., Liu, T., et al. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0737-3 · Cited by 159
Self-citationSimon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., Lardoux, H., Coste, P., Lefèvre, T., Drouet, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.965640 · Cited by 159
Self-citationSavonitto, S., Ferri, L. A., Piatti, L., Grosseto, D., Piovaccari, G., Morici, N., Bossi, I., Sganzerla, P., Tortorella, G., Cacucci, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032180 · Cited by 159
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update
Teng, R. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0290-2 · Cited by 177
Galli, M., Benenati, S., Franchi, F., Rollini, F., Capodanno, D., Biondi‐Zoccai, G., Vescovo, G. M., Cavallari, L. H., Bikdeli, B., ten Berg, J. M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab836 · Cited by 172
Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism
Nylander, S., Femia, E. A., Scavone, M., Berntsson, P., Asztély, A.-K., Nelander, K., Löfgren, L., Nilsson, R. G., & Cattaneo, M. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12360 · Cited by 152
Szummer, K. E., Wallentin, L. C., Lindhagen, L., Alfredsson, J., Erlinge, D., Held, C., James, S. K., Kellerth, T., Lindahl, B., Ravn‐Fischer, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy554 · Cited by 163
Self-citationIschemic Heart Disease: An Update
Jensen, R. V., Hjortbak, M. V., & Bøtker, H. E. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.007 · Cited by 191
Rocca, B., Fox, K. A. A., Ajjan, R., Andreotti, F., Baigent, C., Collet, J., Grove, E. L., Halvorsen, S., Huber, K., Morais, J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy066 · Cited by 157
Self-citationTicagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting
Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Serruys, P. W. J. C., Benit, E., Liebetrau, C., Janssens, L., Ferrario, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1038 · Cited by 163
Self-citationResponse Variability to P2Y12 Receptor Inhibitors
Siller-Matula, J. M., Trenk, D., Schrör, K., Gawaz, M., Kristensen, S. D., Storey, R. F., & Huber, K. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.06.011 · Cited by 165
Self-citationP2Y nucleotide receptors: promise of therapeutic applications
Jacobson, K. A., & Boeynaems, J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.011 · Cited by 174
Adverse Drug Events as a Cause of Hospitalization in Older Adults
Salvi, F., Marchetti, A., D’Angelo, F., Boemi, M., Lattanzio, F., & Cherubini, A. (2012) · Drug Safety · doi:10.1007/bf03319101 · Cited by 177
Goto, S., Ogawa, H., Takeuchi, M., Flather, M. D., Bhatt, D. L., & on behalf of the J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq320 · Cited by 146
Ozaki, Y., Hara, H., Onuma, Y., Katagiri, Y., Amano, T., Kobayashi, Y., Muramatsu, T., Ishii, H., Kozuma, K., Tanaka, N., et al. (2022) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-021-00829-9 · Cited by 164
“These real-world outcomes are consistent with the results of the landmark PLATO (Platelet Inhibition and Patient Outcomes) trial [54].”
ResultPharmacology and Clinical Development of Factor XI Inhibitors
Greco, A., Laudani, C., Spagnolo, M., Agnello, F. G., Faro, D. C., Finocchiaro, S., Legnazzi, M., Mauro, M. S., Mazzone, P. M., Occhipinti, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062353 · Cited by 170
Ferri, N., Corsini, A., & Bellosta, S. (2013) · Drugs · doi:10.1007/s40265-013-0126-z · Cited by 154
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis
Wang, Y., Fang, C., Gao, H., Bilodeau, M. L., Zhang, Z., Croce, K., Liu, S., Morooka, T., Sakuma, M., Nakajima, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70966 · Cited by 157
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Varenhorst, C., Eriksson, N., Johansson, Å., Barratt, B. J., Hagström, E., Åkerblom, A., Syvänen, A., Becker, R. C., James, S. K., Katus, H. A., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv116 · Cited by 146
Self-citationButler, K. A., & Teng, R. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03669.x · Cited by 145
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.23390 · Cited by 406
Navarese, E. P., Khan, S. U., Kołodziejczak, M., Kubica, J., Buccheri, S., Cannon, C. P., Gurbel, P. A., De Servi, S., Budaj, A., Bartorelli, A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.046786 · Cited by 146
“…[NCT01294462] 12 mo NA Ticagrelor 90 mg bid 401 Japanese, Korean, and Taiwanese ACS patients with planned PCI Clopidogrel 75 mg od 400 [PLATO]9 Wallentin et al 2009 NEJM [NCT00391872] 12 mo October 2006 to July 2008 Ticagrelor 90 mg bid 9333 ACS with or without STEMI Clopidogrel 75 mg od…”
MethodSelf-citationO’Donoghue, M. L., Murphy, S. A., & Sabatine, M. S. (2020) · Circulation · doi:10.1161/circulationaha.120.046251 · Cited by 145
Bentzon, J. F., Daemen, M., Falk, E., Garcia-Garcia, H. M., Herrmann, J., Hoefer, I., Jukema, J. W., Krams, R., Kwak, B. R., Marx, N., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-12-0784 · Cited by 143
Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?
Laine, L., & Hennekens, C. H. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.638 · Cited by 142
Rossini, R., Musumeci, G., Visconti, L. O., Bramucci, E., Castiglioni, B., Servi, S. D., Lettieri, C., Lettino, M., Piccaluga, E., Savonitto, S., et al. (2014) · EuroIntervention · doi:10.4244/eijv10i1a8 · Cited by 152
Halvorsen, S., Storey, R. F., Rocca, B., Sibbing, D., ten Berg, J. M., Grove, E. L., Weiss, T. W., Collet, J., Andreotti, F., Gulba, D. C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw454 · Cited by 166
Self-citationDrug Treatment of Acute Ischemic Stroke
Bansal, S., Sangha, K. S., & Khatri, P. (2013) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0007-6 · Cited by 149
Antithrombotic Therapy in the Elderly
Capodanno, D., & Angiolillo, D. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.063 · Cited by 152
The Primary Outcome Is Positive — Is That Good Enough?
Pocock, S. J., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1601511 · Cited by 142
Yang, Y., Kim, T., Yoon, K., Chung, W. S., Ahn, Y., Jeong, M., Seung, K., Lee, S., & Chang, K. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.065 · Cited by 144
Wang, Y., Chen, W., Lin, Y., Meng, X., Chen, G., Wang, Z., Wu, J., Wang, D., Li, J., Cao, Y., et al. (2019) · BMJ · doi:10.1136/bmj.l2211 · Cited by 152
Aradi, D., Komócsi, A., Price, M. J., Cuisset, T., Arı, H., Hazarbasanov, D., Trenk, D., Sibbing, D., Valgimigli, M., & Bonello, L. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.05.100 · Cited by 152
Antiplatelet and anticoagulation for patients with prosthetic heart valves
Massel, D. R., & Little, S. H. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003464.pub2 · Cited by 139
Biondi‐Zoccai, G., Lotrionte, M., Agostoni, P., Abbate, A., Romagnoli, E., Sangiorgi, G., Angiolillo, D. J., Valgimigli, M., Testa, L., Gaita, F., et al. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.035 · Cited by 140
P2Y12 receptors in platelets and other hematopoietic and non-hematopoietic cells
Gachet, C. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9303-x · Cited by 157
Barr, P., Harrison, W., Smyth, D. W., Flynn, C., Lee, M., & Kerr, A. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.02.023 · Cited by 154
Tomaniak, M., Chichareon, P., Onuma, Y., Deliargyris, E., Takahashi, K., Kogame, N., Modolo, R., Chang, C. C., Rademaker-Havinga, T. A. M., Storey, R. F., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3355 · Cited by 141
Self-citationPharmacogenetics to guide cardiovascular drug therapy
Duarte, J. D., & Cavallari, L. H. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00549-w · Cited by 161
P2Y12 platelet inhibition in clinical practice
Damman, P., Woudstra, P., Kuijt, W. J., de Winter, R. J., & James, S. K. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0667-5 · Cited by 140
Self-citation2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0120 · Cited by 177
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 233
REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States
Bhatt, D. L., Miller, M., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044440 · Cited by 136
Self-citationMakki, N. M., Brennan, T. M. H., & Girotra, S. R. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613503294 · Cited by 150
Thomas, M. R., Outteridge, S. N., Ajjan, R., Phoenix, F. A., Sangha, G. K., Faulkner, R. E., Ecob, R., Judge, H. M., Khan, H. Z., West, L. E., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306528 · Cited by 139
Self-citationAntibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Bhatt, D. L., Pollack, C. V., Weitz, J. I., Jennings, L. K., Xu, S., Arnold, S. E., Umstead, B. R., Mays, M. C., & Lee, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901778 · Cited by 140
Adenosine and the Cardiovascular System
Reiss, A. B., Grossfeld, D. J., Kasselman, L. J., Renna, H. A., Vernice, N. A., Drewes, W., Konig, J., Carsons, S. E., & DeLeon, J. R. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00345-5 · Cited by 157
Silvain, J., Lattuca, B., Beygui, F., Rangé, G., Motovska, Z. J., Dillinger, J., Boueri, Z., Brunel, P., Lhermusier, T., Pouillot, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32236-4 · Cited by 137
Roffi, M., Patrono, C., Collet, J., Mueller, C. E., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.10.009 · Cited by 148
Self-citationJones, W. S., Baumgartner, I., Hiatt, W. R., Heizer, G., Conte, M. S., White, C. J., Berger, J. S., Held, P., Katona, B. G., Mahaffey, K. W., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025880 · Cited by 136
Self-citation2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation
Барбараш, О. Л., Duplyakov, D. V., Zateischikov, D. A., Панченко, Е. П., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., Викторович, А. М., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4449 · Cited by 149
Steen, D. L., Khan, I., Andrade, K., Koumas, A., & Giugliano, R. P. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.022198 · Cited by 163
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study
Silvain, J., Cayla, G., Hulot, J., Finzi, J., Kernéis, M., O’Connor, S. A., Bellemain-Appaix, A., Barthélémy, O., Beygui, F., Collet, J. ‐., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr407 · Cited by 139
Roe, M. T., Goodman, S. G., Ohman, E. M., Stevens, S. R., Hochman, J. S., Gottlieb, S., Martínez, F. A., Dalby, A. J., Boden, W. E., White, H. D., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002303 · Cited by 149
Nanhwan, M. K., Ling, S., Kodakandla, M., Nylander, S., Ye, Y., & Birnbaum, Y. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304002 · Cited by 142
Navarese, E. P., Kołodziejczak, M. M., Winter, M., Alimohammadi, A., Lang, I. M., Buffon, A., Lip, G. Y. H., & Siller-Matula, J. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.084 · Cited by 140
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review
Kamran, H., Jneid, H. M., Kayani, W. T., Virani, S. S., Levine, G. N., Nambi, V., & Khalid, U. (2021) · JAMA · doi:10.1001/jama.2021.0716 · Cited by 153
Design and Synthesis of Novel Antimicrobial Agents
Breijyeh, Z., & Karaman, R. (2023) · Antibiotics · doi:10.3390/antibiotics12030628 · Cited by 162
“It works by blocking the platelet adenosine diphosphate P2Y12 receptor to prevent platelet aggregation [163,164].”
BackgroundThe Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin
Patrono, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.012 · Cited by 145
Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease
Wiviott, S. D., Flather, M. D., O’Donoghue, M. L., Goto, S., Fitzgerald, D. J., Cura, F. A., Aylward, P. E., Guetta, V., Dudek, D., Contant, C. F., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.001404 · Cited by 133
Schiele, F., Gale, C. P., Bonnefoy, E., Capuano, F., Claeys, M. J., Danchin, N., Fox, K. A., Huber, K., Iakobishvili, Z., Lettino, M., et al. (2017) · European Heart Journal: Acute Cardiovascular Care · doi:10.1177/2048872616643053 · Cited by 132
Grilz, E., Posch, F., Nopp, S., Königsbrügge, O., Lang, I. M., Klimek, P., Stefan Thurner, A., Pabinger, I., & Ay, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab171 · Cited by 143
Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
Empey, P. E., Stevenson, J. M., Tuteja, S., Weitzel, K. W., Angiolillo, D. J., Beitelshees, A. L., Coons, J. C., Duarte, J. D., Franchi, F., Jeng, L. J. B., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1006 · Cited by 132
Luca, G. D., Bellandi, F., Huber, K., Noc, M., Petronio, A. S., Arntz, H. R., Maioli, M., Gabriel, H. M., Zorman, S., Carlo, M. D., et al. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04513.x · Cited by 131
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
Steg, P. G., Harrington, R. A., Emanuelsson, H., Katus, H. A., Mahaffey, K. W., Meier, B., Storey, R. F., WOJDYLA, D. M., Lewis, B. S., Maurer, G., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002589 · Cited by 134
Self-citationScirica, B. M., Cannon, C. P., Emanuelsson, H., Michelson, E. L., Harrington, R. A., Husted, S., James, S. K., Katus, H. A., Pais, P., Raev, D. H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.056 · Cited by 133
Self-citation
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.